Type6 Therapeutics develops small-molecule kinase inhibitors that target disease-driving kinases in their OFF-states, preventing tumors from accessing escape routes and enhancing treatment durability. Their approach addresses the challenge of evasive tumor responses, offering potent and ultra-selective therapies for aggressive cancers.
Funding
$3.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancer therapies targeting kinases face the challenge of tumors developing resistance through evasive responses. Traditional kinase inhibitors often fail to achieve durable efficacy as tumors find alternative signaling pathways to bypass the drug's effects.
Solution
Type6 Therapeutics develops small-molecule kinase inhibitors designed to target disease-driving kinases in their inactive (OFF) states. This approach aims to prevent tumors from accessing escape routes and enhance treatment durability by intercepting kinases early and upstream of escape points. By engaging kinases in their OFF-states, Type6's inhibitors offer unmatched selectivity, full depth of inhibition, and unprecedented durability in the face of adaptive tumor response, effectively denying tumors access to their preferred escape routes. The company's platform and discovery engine, powered by bivalent chemistry, large-scale compute, and tunable biology, provide exclusive access to a first-in-class mechanism of action.
Target Audience
Type6 Therapeutics targets patients battling aggressive tumors and the clinicians who treat them, as well as pharmaceutical companies seeking novel kinase inhibitors for oncology.
Features
- Small molecule kinase inhibitors and antibody-drug conjugates (ADCs)
- First-in-class mechanism of action that turns target kinase off, takes it out of circulation, and prevents reentry
- Potent, ultra-selective, and prolonged target engagement
- Durable efficacy in the face of evasive tumor response
- Generates assets with single-agent profiles for standalone therapies and logical combinations
- Broadly applicable across clinically validated kinases, directly expandable to CDKs (CMGC), ERBBs (TK), RAFs (TKL)